menu
    • menu
    [{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Alfred E Tiefenbacher GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Posaconazole","moa":"CYP450","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Delayed release tablet","sponsorNew":"Lupin Ltd \/ Alfred E Tiefenbacher GmbH","highestDevelopmentStatusID":"12","companyTruncated":"Lupin Ltd \/ Alfred E Tiefenbacher GmbH"},{"orgOrder":0,"company":"MSN Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Posaconazole","moa":"CYP450","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"MSN Laboratories","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Delayed Release Tablet","sponsorNew":"MSN Laboratories \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"MSN Laboratories \/ Not Applicable"},{"orgOrder":0,"company":"Bajaj Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Posaconazole","moa":"CYP450","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Bajaj Healthcare","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Bajaj Healthcare \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bajaj Healthcare \/ Not Applicable"},{"orgOrder":0,"company":"Mankind Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Posaconazole","moa":"CYP51A1","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Mankind Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Gastro-Resistant Tablet","sponsorNew":"Mankind Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mankind Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Cadila Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Posaconazole","moa":"CYP51A1","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Cadila Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Cadila Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Cadila Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Sumitomo Pharma Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Enzomenib","moa":"Menin and mixed-lineage leukemia interaction","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sumitomo Pharma Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Sumitomo Pharma Oncology \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Sumitomo Pharma Oncology \/ Not Applicable"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Posaconazole","moa":"CYP450","graph1":"Immunology","graph2":"Approved","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Delayed-Release Tablet","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Not Applicable"},{"orgOrder":0,"company":"Endo Pharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Posaconazole","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Endo Pharm","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Endo Pharm \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Endo Pharm \/ Not Applicable"},{"orgOrder":0,"company":"Endo International","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Posaconazole","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Endo International","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Endo International \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Endo International \/ Not Applicable"},{"orgOrder":0,"company":"Fresenius Kabi USA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Posaconazole","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Fresenius Kabi USA","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Fresenius Kabi USA \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Fresenius Kabi USA \/ Not Applicable"},{"orgOrder":0,"company":"Aurobindo Pharma Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Posaconazole","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Aurobindo Pharma Limited","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aurobindo Pharma Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aurobindo Pharma Limited \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Posaconazole

    Menu

    Posaconazole

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
    filter

    Year

    filter

    DEALS // DEV.

    filter

    Country

    filter
    Sponsor
    filter

    Therapeutic Area

    filter

    Study Phase

    filter

    Deal Type

    filter

    Product Type

    filter

    Dosage Form

    filter

    Lead Product

    filter

    Target

    refresh Filters
    refresh Reset Filter
    refresh Reset Filter
    price-trend All Developments

    Therapeutic Area by Lead Product

    ForexGraph

    Study Phase by Lead Product

    ForexGraph

    Company by Lead Product

    ForexGraph

    Top Deals by Deal Size (USD bn)

    ForexGraph

    01

    Dr. Reddy's Laboratories

    India
    CPhI Japan
    Booth #5N-12
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothDRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Lead Product(s) : Posaconazole

    Therapeutic Area : Immunology

    Study Phase : Approved

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Dr. Reddy's Laboratories Announces the Launch of Posaconazole Delayed-Release Tablets in the U.S. Market

    Details : Launch of posaconazole delayed-release tablets, 100 mg, therapeutic generic equivalent to NOXAFIL® (posaconazole) delayed-release tablets, 100 mg approved by U.S.FDA, indicated for prophylaxis of invasive aspergillus and candida infections in patients.

    Product Name : Posaconazole-Generic

    Product Type : Small molecule

    Upfront Cash : Not Applicable

    April 20, 2022

    Lead Product(s) : Posaconazole

    Therapeutic Area : Immunology

    Highest Development Status : Approved

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    Dr Reddy Company Banner

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    02

    Mankind Pharma

    India
    BIO International Convention
    Attending
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothDelivering quality and niche Active Pharmaceutical Ingredients across the global from our USFDA-approved facility.

    Lead Product(s) : Posaconazole

    Therapeutic Area : Infections and Infectious Diseases

    Study Phase : Approved

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Mankind Pharma Launches Drug to Treat Black Fungus

    Details : Posaconazole has been found to be a safer and effective drug of choice for the management of the disease. The drug has received approval from the Drug Controller General of India (DCGI).

    Product Name : Posaforce 100

    Product Type : Small molecule

    Upfront Cash : Not Applicable

    June 10, 2021

    Lead Product(s) : Posaconazole

    Therapeutic Area : Infections and Infectious Diseases

    Highest Development Status : Approved

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    Company Banner

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    03

    Fresenius Kabi USA

    U.S.A arrow
    Immuno-Oncology 360
    Not Confirmed

    Fresenius Kabi USA

    U.S.A arrow
    Immuno-Oncology 360
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Posaconazole

    Therapeutic Area : Infections and Infectious Diseases

    Study Phase : Approved

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Fresenius Launches Posaconazole Injection for Fungal Infection Prevention or Treatment

    Details : Noxafil-Generic (posaconazole) is a CYP451 inhibitor drug, which is indicated for invasive aspergillosis in adults and pediatric patients 13 years of age and older and candida infections.

    Product Name : Noxafil-Generic

    Product Type : Small molecule

    Upfront Cash : Not Applicable

    January 29, 2024

    Lead Product(s) : Posaconazole

    Therapeutic Area : Infections and Infectious Diseases

    Highest Development Status : Approved

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    04

    Aurobindo Pharma Limited

    India arrow
    Immuno-Oncology 360
    Not Confirmed

    Aurobindo Pharma Limited

    India arrow
    Immuno-Oncology 360
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Posaconazole

    Therapeutic Area : Infections and Infectious Diseases

    Study Phase : Approved

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Aurobindo Pharma Gets USFDA Nod for Generic Antifungal Injection

    Details : Noxafil-Generic (posaconazole) is an azole antifungal agent. It is approved for the treatment of prophylaxis of invasive Aspergillus and Candida infections.

    Product Name : Noxafil-Generic

    Product Type : Small molecule

    Upfront Cash : Not Applicable

    December 27, 2023

    Lead Product(s) : Posaconazole

    Therapeutic Area : Infections and Infectious Diseases

    Highest Development Status : Approved

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    05

    Endo International

    Ireland arrow
    Immuno-Oncology 360
    Not Confirmed

    Endo International

    Ireland arrow
    Immuno-Oncology 360
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Posaconazole

    Therapeutic Area : Infections and Infectious Diseases

    Study Phase : Approved

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Endo Launches First Generic Version of Noxafil (posaconazole) Injection

    Details : Posaconazole injection is the inhibition of cytochrome P-450, which is indicated for prophylaxis of invasive Aspergillus and Candida infections in patients who are at high risk of developing these infections due to being severely immunocompromise.

    Product Name : Noxafil-Generic

    Product Type : Small molecule

    Upfront Cash : Not Applicable

    June 29, 2023

    Lead Product(s) : Posaconazole

    Therapeutic Area : Infections and Infectious Diseases

    Highest Development Status : Approved

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    06

    Endo Pharm

    Ireland arrow
    Immuno-Oncology 360
    Not Confirmed

    Endo Pharm

    Ireland arrow
    Immuno-Oncology 360
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Posaconazole

    Therapeutic Area : Infections and Infectious Diseases

    Study Phase : Approved

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Endo Launches Authorized Generic Version of Noxafil® (posaconazole) Oral Suspension

    Details : Posaconazole blocks the synthesis of ergosterol, a key component of the fungal cell membrane, through the inhibition of cytochrome P-450 dependent enzyme lanosterol 14α-demethylase responsible for the conversion of lanosterol to ergosterol in the fungal...

    Product Name : Noxafil-Generic

    Product Type : Small molecule

    Upfront Cash : Not Applicable

    April 03, 2023

    Lead Product(s) : Posaconazole

    Therapeutic Area : Infections and Infectious Diseases

    Highest Development Status : Approved

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    07

    Sumitomo Pharma Oncology

    U.S.A arrow
    Immuno-Oncology 360
    Not Confirmed

    Sumitomo Pharma Oncology

    U.S.A arrow
    Immuno-Oncology 360
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Enzomenib,Posaconazole

    Therapeutic Area : Oncology

    Study Phase : Phase I/ Phase II

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Sumitomo Dainippon Pharma Oncology Announces First Patient Dosed in Phase 1/2 Study of DSP-5336 in Patients wi...

    Details : The primary objectives of the Phase 1 dose escalation portion of the study are to assess the safety and tolerability of DSP-5336 in relapsed or refractory AML or ALL and to determine the recommended Phase 2 dose (RP2D).

    Product Name : DSP-5336

    Product Type : Small molecule

    Upfront Cash : Not Applicable

    March 29, 2022

    Lead Product(s) : Enzomenib,Posaconazole

    Therapeutic Area : Oncology

    Highest Development Status : Phase I/ Phase II

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    08

    Cadila Pharmaceuticals

    India arrow
    Immuno-Oncology 360
    Not Confirmed

    Cadila Pharmaceuticals

    India arrow
    Immuno-Oncology 360
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Posaconazole

    Therapeutic Area : Infections and Infectious Diseases

    Study Phase : Approved

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Cadila Pharma Launches Triazole Antifungal Drug Posaconazole

    Details : Posaconazole is approved for prophylaxis against Aspergillus and Candida infections in immunocompromised patients at high risk for these infections and oropharyngeal candidiasis.

    Product Name : Posacad

    Product Type : Small molecule

    Upfront Cash : Not Applicable

    July 01, 2021

    Lead Product(s) : Posaconazole

    Therapeutic Area : Infections and Infectious Diseases

    Highest Development Status : Approved

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    09

    Bajaj Healthcare

    India arrow
    Immuno-Oncology 360
    Not Confirmed

    Bajaj Healthcare

    India arrow
    Immuno-Oncology 360
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Posaconazole

    Therapeutic Area : Infections and Infectious Diseases

    Study Phase : Approved

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Bajaj Healthcare Launches Posaconazole API for Treatment of Black Fungus Infection

    Details : Posaconazole is a triazole antifungal agent indicated for treating Mucormycosis patients popularly known as Black Fungus in post Covid complications.

    Product Name : Undisclosed

    Product Type : Small molecule

    Upfront Cash : Not Applicable

    May 28, 2021

    Lead Product(s) : Posaconazole

    Therapeutic Area : Infections and Infectious Diseases

    Highest Development Status : Approved

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    10

    MSN Laboratories

    India arrow
    Immuno-Oncology 360
    Not Confirmed

    MSN Laboratories

    India arrow
    Immuno-Oncology 360
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Posaconazole

    Therapeutic Area : Infections and Infectious Diseases

    Study Phase : Approved

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    MSN Labs Launch Indigenous Drug Posaconazole to Treat Black Fungus

    Details : Posaconazole has been launched under the brand name PosaOne as 100 mg Delayed Release tablets and 300 mg injections, respectively. The drug has also been approved by the Drug Controller General of India (DGCI).

    Product Name : PosaOne

    Product Type : Small molecule

    Upfront Cash : Not Applicable

    May 22, 2021

    Lead Product(s) : Posaconazole

    Therapeutic Area : Infections and Infectious Diseases

    Highest Development Status : Approved

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth